Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.


Journal

Nephron
ISSN: 2235-3186
Titre abrégé: Nephron
Pays: Switzerland
ID NLM: 0331777

Informations de publication

Date de publication:
2019
Historique:
received: 14 01 2019
accepted: 10 02 2019
pubmed: 20 3 2019
medline: 1 7 2020
entrez: 20 3 2019
Statut: ppublish

Résumé

A 6-month-old boy presented with acute renal failure, thrombocytopenia, and severe non-immune hemolytic anemia. Infection by Shiga-like toxin-producing Escherichia coli and other causes of microangiopathic hemolysis were ruled out, leading to a diagnosis of atypical hemolytic uremic syndrome (aHUS). Neither pathogenic variants in HUS-associated genes nor anti-factor H antibodies were identified. Copy number variation analysis uncovered 4 copies of complement factor H related genes, CFHR1-CFHR4, conceivably leading to higher than normal levels of the corresponding proteins. However, this abnormality was also found in the healthy relatives, neither explaining the disease nor the excessive complement deposition on endothelial cells detected by an ex-vivo test. Whole-exome sequencing revealed a pathogenic homozygous variant in GRHPR encoding the glyoxylate and hydroxypyruvate reductase. Recessive GRHPR mutations cause primary hyperoxaluria type 2 (PH2). The presence of renal calculi in the patient and elevated oxalate levels in the urine were consistent with the genetic diagnosis of PH2. We hypothesize that, in this patient, hyperoxaluria caused by the GRHPR genetic defect triggered endothelial perturbation and complement activation, which was amplified by impaired factor H regulatory activity due to the increased -CFHR1-CFHR4 copy numbers, resulting in aHUS.

Identifiants

pubmed: 30889567
pii: 000497823
doi: 10.1159/000497823
doi:

Substances chimiques

Apolipoproteins 0
CFHR1 protein, human 0
CFHR4 protein, human 0
Complement C3b Inactivator Proteins 0
Alcohol Oxidoreductases EC 1.1.-
glyoxylate reductase EC 1.1.1.26

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

264-270

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Elisabetta Valoti (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Marta Alberti (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Camillo Carrara (C)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Matteo Breno (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Ebru Yilmaz Keskin (E)

Department of Pediatric Hematology and Oncology, Süleyman Demirel University Medical Faculty, Isparta, Turkey.

Elena Bresin (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Paola Cuccarolo (P)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Yonca Açikgöz (Y)

Pediatric Nephrology, Karadeniz Technical University, Trabzon, Turkey.

Ariela Benigni (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Marina Noris (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy, marina.noris@marionegri.it.

Giuseppe Remuzzi (G)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy.

Caterina Mele (C)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH